Most bought biotechnology stocks in Q2 2023
See which Biotechnology stocks institutional investors increased the most in Q2 2023, measured as net growth in reported share positions from Q1 2023 into Q2 2023. Notable additions at the top of this list include MERUS N V (MRUS). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| MRUS | MERUS N V | 14,021 | $369 | 1 | 0 | 0 | 0 | 1 |
Frequently asked questions about Most bought biotechnology stocks in Q2 2023
What are the most bought Biotechnology stocks in Q2 2023?
The most bought biotechnology stocks in Q2 2023 are those with the largest increase in reported share counts across institutional investors compared to Q1 2023, based on SEC 13F filings.
Which biotechnology stocks did institutional investors added to the most in Q2 2023?
Among filers in this sector, net additions were largest in companies such as MERUS N V (MRUS), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q1 2023).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.